AbCellera Announces Presentation of Phase 1/2 Data for ABCL635 at TMS 2026 Annual Meeting
Business Wire•08/10/2026•16:05 ET
0
Key Highlights
- ➤AbCellera will present Phase 1/2 ABCL635 data at TMS 2026.
- ➤Presentation includes new Phase 1 multiple-ascending-dose safety data.
- ➤Presentation includes new Phase 2 patient-reported outcome data.
- ➤ABCL635 targets menopause-related moderate-to-severe vasomotor symptoms.
AbCellera Announces Presentation of Phase 1/2 Data for ABCL635 at TMS 2026 Annual Meeting
AbCellera (Nasdaq: ABCL) today announced an upcoming poster presentation of Phase 1/2 data on ABCL635 at The Menopause Society’s (TMS) 2026 Annual Meeting, to be held October 20 to 24 at the Hilton Bayfront in San Diego, California.
Get started
Create a free account to read the full story.